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ABSTRACT 
Although the stimulating effect of insulin-like growth factor I 
(IGF-I) on adrenal steroidogenesis has been well established, the role 
of IGF-II in the adult adrenal gland remains unknown. We, therefore, 
investigated the effect of recombinant human IGF-II on cortisol and 
CAMP synthesis from adult bovine adrenocortical cells. IGF-II, time 
and dose dependently, stimulated basal cortisol secretion maximally 
3-fold. In combination with ACTH, IGF-II (13 nM) synergistically 
increased cortisol secretion from 18-fold (lo- ’ M ACTH) to 28-fold of 
untreated control levels. In contrast, IGF-I at equimolar concentra- 
tions did not show an effect on basal cortisol secretion, and in com- 
bination with ACTH elicited a significant weaker stimulatory effect 
than IGF-II (22-fold increase). The synergistic effect of IGF-II on 
ACTH-promoted cortisol secretion was paralleled by accumulation of 
CAMP in the culture medium. Although both IGF receptors are 
present in adult bovine adrenocortical cells, the effect of IGF-II seems 
to be mediated through interaction with the IGF-I receptor, as 
IArg”“~““lIGF-11, which only binds to the IGF-I receptor, was equipo- 
tent to native IGF-II, whereas [LeuZ711GF-II, which preferentially 
binds to the type II IGF receptor, did not show any effect. By Western 
ligand blotting, four different molecular forms of IGF-binding 
proteins (IGFBPs) were identified in conditioned medium of bovine 
adrenocortical cells with apparent molecular masses of39-44,34,29, 
and 24 kilodaltons. ACTH treatment increased the abundance of all 
binding proteins, on the average, 2.3-fold, except for the 29-kDa band, 
which was predominantly induced 6.8-fold. Additionally, Ides’-“]IGF- 
I, a truncated IGF variant that exhibits only minimal binding to 
IGFBPs, was significant more potent than IGF-I and elicited the same 
maximum stimulatory effect on cortisol secretion as IGF-II and 
[des’-“lIGF-II. 
In conclusion, these results demonstrate that 1) IGF-II stimulates 
basal as well as ACTH-induced cortisol secretion from bovine adre- 
nocortical cells more potently than IGF-I; 2) this effect is mediated 
through interaction of IGF-II with the IGF-I receptor; 3) bovine ad- 
renocortical cells synthesize various IGFBPs that are induced differ- 
entially by ACTH; and 4) IGFBPs apparently play a modulatory role 
in IGF-induced stimulation of adrenal steroidogenesis. Therefore, 
bovine adult adrenocortical cells provide a useful tissue culture model 
in which the interactions among locally produced IGFs, IGFBPs, and 
the IGF-I receptor can be evaluated. (Endocrinology 136: 3714-3720, 
1995) 
T HE INSULIN-LIKE growth factors (IGF-I and IGF-II) are polypeptides, structurally related to proinsulin, that 
have been implicated in the hormonal regulation of growth 
and differentiation. IGF-I mediates the growth-promoting 
effects of GH in postnatal life, whereas IGF-II seems to be 
involved in the regulation of fetal growth. IGFs show mito- 
genie and differentiation-promoting activities in a variety of 
tissues in which they are produced locally and presumably 
act in a paracrine/autocrine manner (l-4). Both ligands in- 
teract with specific cell surface receptors, to which they bind 
with differing affinities. The type I IGF receptor is a het- 
erotetramer transmembrane receptor, structurally related to 
the insulin receptor. It contains an intracellular tyrosine ki- 
nase domain and binds with high affinity to IGF-I and with 
only slightly weaker activity to IGF-II. The structurally dis- 
tinct type II IGF receptor is identical to the cation-indepen- 
dent mannose-6-phosphate receptor (IGF-II/M6P receptor) 
and preferentially binds IGF-II with high affinity (5). Al- 
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though most effects of IGF-I and IGF-II are mediated through 
interaction of the ligands with the type I IGF receptor, the role 
of the IGF-II/M6P receptor in IGF signaling remains con- 
troversial (6, 7). Furthermore, the IGFs bind to a variety of 
IGF-binding proteins (IGFBPs) that are present in many tis- 
sues and body fluids and take part in the regulation of IGF 
action (8, 9). 
There are accumulating data that IGFs play an important role 
in the regulation of growth and differentiation of the adrenal 
gland. Previous studies in several species have demonstrated 
the presence of IGF-I/II messenger RNA (mRNA) and peptide 
(10-13) as well as IGF receptors in the adrenal gland (14-18). 
Furthermore, IGFs elicit mitogenic and differentiating effects in 
human adrenal cells in vitro (19-22). In bovine adrenocortical 
cells, IGF-I potentiates ACTH-induced cortisol secretion, up- 
regulates ACTH receptors, and increases the mRNA abundance 
of various steroidogenic enzymes (15, 23-26). In the rat, how- 
ever, an inhibitory role of IGF-I on steroid biosynthesis has been 
described (27), and IGF-II, but not IGF-I, in combination with 
insulin is mitogenic for fetal adrenal cells (28). 
So far, all effects of IGF in adult adrenal cells have been 
attributed to IGF-I, whereas IGF-II is assumed to modulate 
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fetal adrenal cell growth and differentiation. In the human 
fetal adrenal gland, IGF-II expression is high and up-regu- 
lated by ACTH (19), IGF-II enhances the steroidogenic re- 
sponse to ACTH (20), and both IGFs stimulate fetal adrenal 
cell proliferation (19). Increased IGF-II mRNA levels were 
found in human adrenocortical tumors (29). 
As the role of IGF-II in the regulation of the adult adre- 
nocortical cell has not been investigated so far, we evaluated 
the effect of IGF-II on the basal and ACTH-stimulated ste- 
roidogenic responses of cultured bovine adrenocortical cells. 
As we have previously shown, these cells are responsive to 
IGF-I (26) and express both types of IGF receptors, with the 
IGF-II/M6P receptor being twice as abundant as the IGF-I 
receptor (18). 
In the present study, we demonstrate that in bovine ad- 
renocortical cells, IGF-II has a stronger stimulatory effect on 
cortisol secretion than IGF-I. By incubation experiments with 
mutant IGF ligands, we show that the effect of IGF-II is 
mediated through interaction with the IGF-I receptor and 
that the different potencies of IGF-I and IGF-II may be due 
to interaction of the ligands with IGFBPs. At least four dif- 
ferent forms of IGFBPs are secreted by bovine adrenocortical 
cells, and their abundance is up-regulated by ACTH. 
Materials and Methods 
Materials 
Recombinant human IGF-I and IGF-II were purchased from Boehr- 
inger (Mannheim, Germany); mutant recombinant Ides’-“JIGF-I and 
[des’-“IIGF-II were obtained from GroPep (Adelaide, Australia). 
[Leu”‘]IGF-II and [Arg ‘“,i’JIGF-II, mutant recombinant human IGF-II 
analogs, were kindly provided by Daiichi Pharmaceutical Co. (Tokyo, 
Japan). (3-[“i]iodotyrosyl)IGF-I and IGF-II (human recombinant; SA, 
2000 Ci/mmol) were purchased from Amersham Buchler and CoKG 
(Braunschweig, Germany), and [“‘Ilcortisol was obtained from Sorin 
Biomedica (Braunschweig, Germany). 
Cell preparation and culture conditions 
Monolayer cell cultures of adult bovine adrenocortical cells were 
prepared as previously described (30). In brief, bovine adrenocortical 
tissue was enzymatically dispersed with 1% collagenase II and 0.075% 
deoxyribonuclease I (75 min at 37 C), filtered (100 km), and centrifuged 
(Ymui at .415V‘X s),‘ iSi ‘bldod ‘ceil< and ‘ceil’d&rlS were removed ‘bji 
washing with PBS followed by Percoll centrifugation (p = 1.07 g/ml; 37 
C; Pharmacia, Uppsala, Sweden) for 10 min at 730 X s. The band 
containing adrenocortical cells was resuspended in cell culture medium 
[medium 199 containing 10% fetal calf serum, 5% horse serum, L-&I- 
tamine (292 fig/ml), gentamycin (52 &ml), and amphotericin B (0.5 
pg/ml)] and adrenocortical cells were grown in monolayers at 37 C in 
a humidified atmosphere with 95% air-5% CO, for 2 days in 22-mm 
multiwell plates. Twenty-four hours before the experiments, the me- 
dium was exchanged to serum-free medium [medium 199 containing 
L-glutamine (292 pg/ml), gentamycin (52 Fg/ml), and amphotericin B 
(0,5 fig/ml)]. At confluency, cell density was 3.28 2 0.5 X lO‘cells/well, 
and cell viability was greater than 920/r, as confirmed by trypan blue 
exclusion after 96 h of incubation. 
Experimental procedure 
Bovine adrenocortical cells (l-3 X 10’ cells/well) were incubated 
with 1 ml serum-free medium with or without ACTH (10 ‘M) and IGFs 
at the indicated concentrations for up to 96 h. At the time points indi- 
cated, medium was aspirated and stored at -30 C for further analysis. 
At the end of each experiment, cell number was measured with a Coulter 
counter (Coulter Electronics, Hialeah, FL). Cortisol secreted into the 
medium was determined by specific RIA, as previously described (31). 
The standard curve demonstrated an ED?,, of 500 rig/ml and an ED,,, of 
5 rig/ml. All samples were diluted to fall on the linear part of the curve 
between these two values. The intra- and interassay coefficients of vari- 
ation of this assay were less than 10%. The amount of CAMP in the 
medium was measured by the [“‘IJcAMP assay system from Amersham 
(Braunschweig, Germany). Assays were performed in duplicate, and all 
experiments were repeated at least six times with independent cell 
preparations. Treatment with ACTH induced a dose-dependent increase 
in cortisol secretion, with a half-maximal stimulation at 10 ’ M ACTH. 
Western ligand blotting 
Bovineadrenal cells were incubated for 48 h with or without ACTH 
(lo-’ M) under serum-free conditions. The medium corresponding to 
3 X 10h cells was harvested and concentrated, and samples were 
separated by 12% sodium dodecyl sulfate-polyacrylamide gel elec- 
trophoresis under nonreducing conditions in a Laemmli buffer sys- 
tem. Proteins were electrotransblotted onto nylon membranes (Imo- 
bilon, Milipore, Munich, Germany). The IGFBPs were identified by 
autoradiography after overnight incubation of the filters with 12% 
labeled IGF-I or IGF-II at 4 C. The relative amount of each band was 
quantified by cutting the corresponding bands on the membrane and 
counting in a y-counter. 
Statistics 
Data are depicted as the mean 2 SEM, and differences between treat- 
ment groups were assessed by nonpaired t testing. 
Results 
IGF-II action in adult bovine adrenocortical cells 
In time-course experiments, adult bovine adrenocortical 
cells were treated with IGF-I or IGF-II (13 nM) with or without 
the addition of ACTH (lop8 M) for up to 48 h (Fig. 1). The 
addition of IGF-I alone (13 nM) led to a moderate increase in 
basal cortisol secretion, which was significant after 48 h (2.4- 
fold of control value; P < 0.05). In contrast, IGF-II (13 nM) 
stimulated basal cortisol secretion significantly after 12 h (P 
< O.Ol), with a 3.3-fold increase after an incubation time of 
1.1 
0.9- 
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FIG. 1. Time course of IGF action on basal and ACTH-stimulated 
cortisol secretion in primary bovine adrenocortical cells. Cells (1 x 
10’) were incubated in multiwell plates for 48 h in the presence of 
ACTH (10 ’ M), IGF-I, or IGF-II (13 nM). At each time point, medium 
was aspirated and assayed for cortisol. Eachpoint represents six wells 
(mean 2 SEM). Data are representative of a single experiment 
performed independently at least six times. 
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48 1~. The stimulatory effect of IGF-II on cortisol secretion was 
stronger than the effect of IGF-I at all time points tested. As 
expected, the addition of ACTH (lo-’ M) led to a marked 
maximal 19-fold increase in basal cortisol secretion after 48 
h. IGF-II (13 nM) in combination with ACTH (lo-’ M) showed 
a synergistic stimulatory effect on cortisol secretion by pri- 
mary bovine adrenocortical cells, with a 29-fold increase in 
cortisol levels after 48 h. A significant stimulatory effect of 
IGF-II on ACTH-induced cortisol secretion was observed 
after 12 h of incubation (3-fold increase in ACTH-induced 
cortisol levels; P < 0.021, and maximum cortisol levels were 
reached after 24 h. In contrast, IGF-I in the same concentra- 
tion was significantly less effective than IGF-II at enhancing 
ACTH-stimulated cortisol secretion (22-fold increase), and 
maximum levels of cortisol were reached only after 48 h of 
incubation. 
The stimulatory effect of IGFs on basal as well as ACTH- 
induced cortisol secretion was paralleled by an increase in 
the accumulation of CAMP in the supernatant (Fig. 2). As 
expected, ACTH (lo-’ M) was a potent stimulator of CAMP 
levels in the medium, with an increase from 2.4 to 29 
pmol/ml after an incubation period of 48 1~. Maximal levels 
of CAMP (49.3 pmol/ml) were achieved with a combination 
of ACTH and IGF-II (3, 2 nM), whereas the combination of 
ACTH and IGF-I was significantly less potent (39.6 pmol/ 
ml). Treatment with IGF-II alone caused only a slight increase 
in CAMP and cortisol levels, and IGF-I alone had no effect. 
No mitogenic effect of either ligand on cell number was 
observed (data not shown). 
Dose-response experiments with IGF-I and IGF-II in com- 
bination with ACTH showed that both ligands at very high 
concentrations (26-52 nM) maximally stimulated ACTH-in- 
duced cortisol secretion more than 3-fold (Fig. 3). Addition- 
ally, an equimolar combination of both IGFs at high doses did 
not elicit a further stimulatory effect. However, at low con- 
centrations (0.4-0.8 nM), IGF-I did not show any significant 
stimulatory effect on cortisol secretion, whereas IGF-II pro- 
duced half-maximal stimulation (P < 0.005). In contrast to 
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FIG. 2. Effects of ACTH and IGFs on CAMP and cortisol production 
in primary bovine adrenocortical cells. Cells (3 X 10”) were incubated 
in- mukiwel!- plates for.-48 h-in- the- presence-of ACTH (10.: s MS,-IGF--I,- 
or IGF-II (3.2 nM). After incubation for 48 h, medium was aspirated, 
pooled, and assayed for CAMP (ml and cortisol (Ml. Each bar repre- 
sents pooled samples of three independently performed experiments 
(mean 5 SEMI. ‘*, P < 0.05; ‘i::B, P < 0.01 (US. ACTH group). 
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FIG. 3. Dose response of effect of IGF on ACTH-induced cortisol se- 
cretion in primary bovine adrenocortical cells. Cells (2 X 10”) were 
incubated in multiwell plates in the presence of ACTH (10~ s M) and 
the indicated concentrations of IGF-I or IGF-II. After incubation for 
36 h, medium was aspirated and assayed for cortisol. Each point 
represents at least six wells (mean 2 SEM). Data are representative 
of four separate experiments. 
IGF-II, the stimulatory effect of IGF-I was only significant for 
doses greater than 0.8 nM (P < 0.01). The mean IGF concen- 
trations required for a half-maximal stimulation of ACTH- 
induced cortisol secretion (ED,,,) in four separate experi- 
ments were 10 and 0.9 nM for IGF-I and IGF-II, respectively. 
Similar differences in the potencies of IGF-I and IGF-II were 
observed in dose-response experiments without ACTH (data 
not shown). 
Action of mutant IGF ligands on cortisol secretion 
To investigate the role of the IGF-I and the IGF-II/M6P 
receptor in mediating the effect of IGF-II in our cell system, 
two different mutant IGF-II ligands were used (32). 
[Leu27]IGF-II, containing a leucine substitution for tyrosine 
at amino acid position 27, exhibits high affinity (Kc, = 0.05 
nM) for the type II IGF receptor but only low affinity (Kd = 
66 nM) for the type I IGF receptor. In contrast, [Args1,5”]IGF- 
II, containing an arginine substitution for alanine- and 
leucine-55, displays a high affinity (K, = 0.4 nM) for the IGF-I 
receptor and no binding to the IGF-II/M6P receptor (32). 
[Leu2’]IGF-II (3.2 nM) failed to stimulate ACTH-induced cor- 
tisol secretion in primary bovine adrenocortical cells despite 
the presence of IGF-II/M6P receptors in these cells (18). 
However, [Arg”“~s5]IGF-II, which binds to the IGF-I receptor, 
but not to the IGF-II/M6P receptor, stimulated cortisol se- 
cretion in bovine adrenal cells to a similar extent as equimolar 
concentrations of native IGF-II (Fig. 4). This confirms that the 
effect of IGF-II on cortisol synthesis in bovine adrenocortical 
cells is mediated through interaction of the IGF ligands with 
the IGF-I and not with the IGF-II/M6P receptor. Similar data 
were obtained when the cells were incubated with mutant 
ligands without the addition of ACTH (data not shown). 
To elucidate a possible modulatory role of IGFBPs on the 
bioactivity ofI@i;‘-i’and ‘RX-B ‘in our ceilsystem, mutantIGF 
ligands with reduced affinities for IGFBPs were used (Fig. 5). 
[des’-“IIGF-I and [des’-h]IGF-II are truncated IGF variants 
lacking the first three and six N-terminal amino acids, 
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FIG. 4. Effects of mutant IGF-II ligands with altered binding to the 
IGF-I receptor on cortisol secretion in primary bovine adrenocortical 
cells. Cells (2 X 105) were incubated in multiwell plates in the pres- 
ence of ACTH (10d8 M) and mutant or native IGF ligands (3.2 11~1. 
After incubation for 48 h, medium was aspirated and assayed for 
cortisol. Each bar represents 11 wells (mean t SEM). *, P < 0.05; **, 
P < 0.01 (us. IGF-I group). Data are representative of a single 
experiment performed independently at least four times. 
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FIG. 5. Effects of mutant IGF ligands with decreased binding to IG- 
FBPs on cortisol secretion in primary bovine adrenocortical cells. 
Cells (2 X lo61 were incubated in multiwell plates in the presence of 
ACTH (10-s M) and mutant or native IGF ligands (3.2 no). ARer 
incubation for 48 h, medium was aspirated and assayed for cortisol. 
Each bar represents at least 16 wells (mean t SEM). *, P < 0.05; **, 
P < 0.01 (US. IGF-I group). Data are representative of five separate 
experiments. 
respectively. Both show substantially decreased binding to 
IGFBPs whereas their affinities for the IGF receptors remain 
unaltered ([des’“lIGF-I) or are slightly reduced (des[‘-61 
IGF-II) (33). When ACTH-primed cells were treated with 
[des’“lIGF-I (3.2 nM instead of native IGF-I, a significantly 
stronger stimulatory effect on ACTH-induced cortisol secre- 
tion was observed (2.2- vs. 3-fold increase in ACTH-stimu- 
lated control value; P < 0.02). In contrast, [des’-611GF-II (3.2 
nM) stimulated ACTH-induced cortisol secretion to a similar 
extent as native IGF-II and [des’“lIGF-I. The fact that 
[des’-311GF-I was equipotent to IGF-II points to a modulatory 
role of IGFBPs in the regulation of IGF-stimulated cortisol 
secretion in bovine adrenal cells. 
Secretion of IGFBPs by bovine adrenocortical cells 
To identify IGFBPs synthesized by adult bovine adreno- 
cortical cells, ligand blotting of cell-conditioned medium was 
performed with [‘25111GF-I and [‘25111GF-II. As shown in Fig. 
6, the medium of untreated control cells contains at least four 
specific bands, with a doublet of 39-44 kDa and additional 
bands at 34, 29, and 24 kDa. When cells were treated with 
ACTH, the intensities of all bands were markedly, but dif- 
ferentially, increased. Quantitative analysis of the IGFBP 
bands of eight independent experiments indicated that in 
unstimulated cells, the 39-/44-kDa doublet band accounts 
for almost half of the detected IGFBP activity (46 t: 5%), 
followed by the 29-kDa (26 + 3%), the 24-kDa (15 ? 2%), and 
the 34-kDa (13 t 2%) bands. A similar binding pattern was 
observed when bovine serum or cytosol extracts of bovine 
adrenocortical cells were analyzed by Western ligand blot- 
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FIG. 6. Western ligand blot of IGFBPs secreted by bovine adreno- 
cortical cells. Cells were incubated with serum-free medium alone 
(lane A) or ACTH (lo-’ M; lane B) for 48 h. Conditioned medium was 
concentrated, separated by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis under nonreducing conditions, transferred to ni- 
trocellulose, incubated with ‘a51-labeled IGF-I, and autoradio- 
graphed. Data are representative of eight independent experiments. 
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ting (data not shown). When bovine adrenocortical cells in 
primary culture were treated with ACTH (lo- ’ M for 48 h), 
the abundance of all IGFBPs in the culture medium was 
up-regulated, on the average, 2.3-fold, except for the 29-kDa 
band, which was preferentially stimulated 6.8-fold over the 
unstimulated control group value. The stimulatory effect of 
ACTH on the abundance of IGFBPs in our cell system was 
significant greater than the observed unspecific increase in 
protein concentration in the culture medium after treatment 
with ACTH (133% of the control value). No difference in the 
basal and ACTH-induced binding patterns was observed 
when [‘251]IGF-II was used as a radioligand. 
Discussion 
In the studies reported here, we present an adrenal cell 
culture system in which IGF-II, through interaction with the 
IGF-I receptor, is signaling more potently than IGF-I. Our 
data demonstrate that in primary culture of adult bovine 
adrenocortical cells, IGF-II stimulates basal as well as ACTH- 
induced cortisol and CAMP secretion 10 times more potently 
than IGF-I. This effect is mediated through interaction of both 
ligands with the IGF-I receptor. The different efficacies of 
both IGFs might be explained by a modulatory role of IG- 
FBI’s, which are produced locally by the adrenocortical cells. 
Therefore, bovine fasciculata cells provide a readily available 
cell culture system in which the role of IGFBPs in modulating 
IGF signaling through the IGF-I receptor can be evaluated. 
In the present studies, recombinant human IGF-II at phys- 
iological concentrations (34) stimulated basal as well as 
ACTH-induced cortisol secretion in a dose-dependent way. 
This effect was significant after 12 h and reached its maxi- 
mum after 24 h. Although treatment with IGF-II alone elic- 
ited only a moderate 3-fold increase in cortisol output, the 
effect of IGF-II on ACTH-induced cortisol secretion (19-fold 
stimulation) was synergistic, with a 29-fold increase in basal 
cortisol secretion. In dose-response experiments, both IGFs at 
a pharmacological dose (52 nM) stimulated ACTH-induced 
cortisol secretion to a similar extent, and no additive effect of 
both ligands was observed. At physiological concentrations, 
however, the dose-response curve of IGF-II was significantly 
shifted to the left compared to that of IGF-I. IGF-II was 10 
times more effective in increasing ACTH-stimulated cortisol 
secretion (ED,,, = 0.9 nM) than IGF-I (ED,,, = 10 nM). The 
observed effect of IGF-I on basal and ACTH-induced cortisol 
and CAMP secretion in adult bovine adrenocortical cells is in 
accordance to previous reports of an IGF-I-stimulated ste- 
roidogenic response in bovine (15,241, ovine (21), and human 
(22) adrenal cells. In rats, however, an inhibitory effect of 
IGF-I on ACTH-induced steroidogenesis in isolated adrenal 
cells has been described (27). The only study on the effect of 
IGF-II on adrenal hormone secretion reports a stimulatory 
effect of IGF-II on ACTH-induced cortisol secretion in human 
fetal adrenal cells (20). This is in good accordance with our 
findings in adult bovine adrenocortical cells. Our observa- 
tion that IGF-II is more potent than IGF-I in stimulating 
bovine adrenocortical steroidogenesis supports the hypoth- 
esis that IGF-II is an important regulator of adrenocortical 
cell function. A predominant role of IGF-II in the autocrinel 
paracrine regulation of adrenal steroidogenesis has been pos- 
tulated previously from a coordinate expression of IGF-II 
and steroidogenic enzyme mRNAs in fetal human and ovine 
adrenal glands (11, 35). 
As we reported, bovine adrenocortical cells express both 
types of IGF receptors (18). However, in most cell systems the 
effects of both IGFs are mediated through interaction with 
the IGF-I receptor (2, 36). As the IGF-I receptor in our cell 
system exhibits a slightly higher affinity for IGF-I than for 
IGF-II, with a half-maximal competition for [ ‘2”I]IGF-I bind- 
ing by 0.8 and 6.5 nM unlabeled IGF-I and IGF-II, respectively 
(I@, a stronger biological effect of IGF-I compared to that of 
IGF-II would have been expected. Therefore, the observed 
IO-fold stronger bioactivity of IGF-II compared to that of 
IGF-I is in contrast to their affinities for the IGF-I receptor. 
Taking into account that bovine adrenocortical cells contain 
far more IGF-II/M6P receptors than IGF-I receptors (18), the 
dose-response experiments do not allow us to assign the 
effect of IGF-II to a specific IGF receptor. The facts that the 
maximum responses of IGF-I and IGF-II were the same, and 
no synergistic effect by the combination of both ligands was 
observed provide indirect evidence that the stimulatory ef- 
fect of both IGFs is mediated through the same receptor. 
Although the type II IGF receptor is abundant in bovine 
adrenocortical cells, and the concentration of unlabeled 
IGF-II required to displace 50% of labeled IGF-II bound to 
this receptor (1.8 nM) is similar to the dose of IGF-II necessary 
for a half-maximal stimulatory effect (0.9 nM), it is unlikely 
that both ligands mediate their effects through the IGF-II/ 
M6P receptor. IGF-I only in micromolar concentrations 
shows binding to the IGF-II/M6P receptor, and the role of the 
IGF-II/M6P receptor in IGF signaling remains controversial 
(7). By treating bovine adrenocortical cells with mutant 
IGF-II ligands that bind with different affinities to the type 
I and type II IGF receptor, we confirmed that in these cells 
the effect of IGF-II is mediated through interaction with the 
IGF-I receptor, and that IGF-II/M6P receptors are not re- 
quired for stimulation of cortisol secretion by IGF-II. Thus, 
[Arg i’,55]IGF-II, which does not bind to the IGF-II/M6P re- 
ceptor, but shows high affinity for the IGF-I receptor, was 
equipotent to IGF-II. In contrast, [Leu27]IGF-II, which has a 
high affinity for the IGF-II receptor, but exhibits only 
minimal binding to the IGF-I receptor, was ineffective in 
stimulating cortisol secretion. 
The mechanism by which IGFs increase ACTH-stimulated 
steroidogenesis in adrenal cells remains unclear (20). Previ- 
ous studies show that in bovine adrenocortical cells, IGF-I 
up-regulates ACTH receptors, whereas ACTH stimulates the 
abundance of IGF-I receptors and the secretion of an IGF-I- 
like peptide (12,24,37). To further elucidate the mechanism 
by which IGF-II, through interaction with the IGF-I receptor, 
modulates the steroidogenic response to ACTH, we mea- 
sured the concentration of CAMP in the culture medium. As 
reported previously, the increase in CAMP in the medium of 
intact adrenocortical cells reflects the intracellular action of 
adenylate cyclase due to ACTH stimulation (38). In our study 
we found that IGF-I and, more potently, IGF-II stimulate 
ACTH-induced CAMP accumulation in the medium of adult 
bovine adrenocortical cells. This increase correlates closely 
with the effects of IGF-I and IGF-II on cortisol secretion in the 
ADRENAL IGF-II SIGNALING 3719 
same cells. The facts that the synergistic effect of IGF-II on 
ACTH-promoted cortisol secretion was paralleled by the 
accumulation of CAMP, and that IGF-II predominantly stim- 
ulates ACTH-induced steroidogenesis, but has only a weak 
stimulatory effect by itself support the hypothesis that up- 
regulation of the ACTH receptor by IGF-II is an important 
mechanism for the IGF-induced increase in the sensitivity of 
bovine adrenocortical cells to ACTH. 
As the discrepant potency of IGF-I and IGF-II in our cell 
system might be explained by interaction of these ligands 
with IGFBPs, we performed incubation experiments with 
IGF variants exhibiting reduced affinities for IGFBPs. 
[des’-“IIGF-I, which exhibits unaltered affinity for the IGF-I 
receptor, but weak or almost no binding to IGFBPs, showed 
a significantly stronger stimulatory effect on ACTH-induced 
cortisol secretion than native IGF-I. In contrast, [des’-“IIGF- 
II, a truncated form of IGF-II that binds poorly to IGFBPs but 
also has a reduced affinity for the IGF-I receptor (33), was 
equipotent to wild-type IGF-II and ldes’~“lIGF-I. As the poor 
binding of [desim3]IGF-I to IGFBPs correlates well with its 
increased bioactivity in our cell system, a preferential inter- 
action of IGF-I with an inhibitory IGFBP would be sufficient 
to explain the different stimulatory potencies of the two IGFs 
in bovine adrenocortical cells. This mechanism has been pos- 
tulated for various other cell systems in which increased 
bioactivity of [des’-“IIGF-I compared to that of native IGF-I 
has been found (9, 33). However, IGFBPs are able to mod- 
ulate the action of IGF through a variety of mechanisms (9), 
and our results do not conclusively show through which 
binding protein and what mechanism the modulatory effect 
of IGFBPs in our cell system is exerted. As many IGFBPs 
exhibit a greater affinity for IGF-II, it is equally valid to 
consider the hypothesis that in this cell system, IGF-II may 
be preferentially bound by IGFBPs that are capable of ad- 
hering to the cell surface, thus promoting the interaction of 
IGF-II with the IGF-I receptor (9). 
At least four different IGFBPs are synthesized by bovine 
adrenal cells, as assayed by Western ligand blotting of con- 
ditioned medium. The 39-44 kDa doublet detected in con- 
ditioned medium of our cell system corresponds in mol wt 
to different glycosylation states of IGFBP-3 and was found to 
be of similar size in control samples of bovine serum. Al- 
though the sizes of the 34-, 29-, and 24-kDa bands would be 
compatible with IGFBP-2, IGFBP-5 or -6, and IGFBP-4, re- 
spectively, the exact identification of the various bands re- 
quires further confirmation. A similar binding pattern for 
IGFBPs has previously been reported for bovine adrenal 
fasciculata cells (39), cultured bovine fibroblasts (40), and 
human fetal adrenal cells (41). In contrast to the findings in 
adult bovine adrenocortical cells, no regulation of IGFBPs by 
ACTH has been observed in human fetal adrenal cells, which 
might be due to developmental or species-specific differ- 
ences (41). The fact that in adult bovine adrenocortical cells, 
IGFBPs are differentially up-regulated by treatment with 
ACTH may contribute to the complex mechanism of ho- 
meostasis and modulation of IGF action in the adrenal gland. 
At the cellular level, both inhibition and stimulation of IGF- 
mediated action by IGFBPs have been reported. However, 
the precise mechanism by which IGFBPs modulate IGF 
signaling remains speculative (9). 
Our data support the hypothesis that interactions between 
IGFs and locally produced IGFBPs with the IGF-I receptor 
play an important role in the regulation of adrenal steroi- 
dogenesis. The possible interactions of two related IGF li- 
gands with two types of IGF receptors and several different 
IGFBPs in the same cellular environment explain part of the 
difficulties in understanding the molecular mechanism of 
IGF signaling. Therefore, bovine adrenocortical cells provide 
a useful tool to further evaluate the role of IGFBPs in 
modulating IGF signaling at the cellular level. 
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